Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers
(1) Background: The purpose of this study was to evaluate the time toxicity, or time spent in health care, of immunotherapy- versus chemotherapy-based regimens for metastatic esophageal and gastric cancers. (2) Methods: A literature search was conducted, and 18 phase III clinical trials of immune ch...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/23/5677 |
| _version_ | 1797400301050789888 |
|---|---|
| author | Neha Y. Agrawal Rajat Thawani Corbin P. Edmondson Emerson Y. Chen |
| author_facet | Neha Y. Agrawal Rajat Thawani Corbin P. Edmondson Emerson Y. Chen |
| author_sort | Neha Y. Agrawal |
| collection | DOAJ |
| description | (1) Background: The purpose of this study was to evaluate the time toxicity, or time spent in health care, of immunotherapy- versus chemotherapy-based regimens for metastatic esophageal and gastric cancers. (2) Methods: A literature search was conducted, and 18 phase III clinical trials of immune checkpoint inhibitors were selected for analysis. Health care days were calculated based on the number of days associated with receiving therapy and the adverse events reported in the clinical trials. Both the number of health care days and the median overall survival were compared among chemotherapy-only, immunotherapy-only, and chemo-immunotherapy regimens across this cohort of drug registration trials. (3) Results: The estimated median number of health care days was 37 (range of 7–52) days, or 1.2 (range of 0.2–1.7) months, compared to a median survival of 10.2 months across these 18 studies. For the chemotherapy-only regimens, the median number of health care days was 39 (range of 21–51) days, and for chemo-immunotherapy, it was 39 (range of 30–52) days. The immunotherapy-only regimens had fewer days, a median of 28 (range of 24–41), <i>p</i> < 0.05, compared to the other two arms. (4) Conclusions: The chemo-immunotherapy regimens did not add time toxicity compared to chemotherapy alone. The immunotherapy-only regimens had lower time toxicity compared to chemotherapy alone. In the setting of decreased time toxicity and improved overall survival, further development of immunotherapy-based regimens could improve outcomes in advanced esophageal and gastric cancers. |
| first_indexed | 2024-03-09T01:53:34Z |
| format | Article |
| id | doaj.art-2995e5b539624708babab6b135c152ac |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T01:53:34Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2995e5b539624708babab6b135c152ac2023-12-08T15:12:54ZengMDPI AGCancers2072-66942023-11-011523567710.3390/cancers15235677Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric CancersNeha Y. Agrawal0Rajat Thawani1Corbin P. Edmondson2Emerson Y. Chen3Department of Medicine, Oregon Health & Science University, Portland, OR 97239, USADepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USADepartment of Medicine, Oregon Health & Science University, Portland, OR 97239, USADivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA(1) Background: The purpose of this study was to evaluate the time toxicity, or time spent in health care, of immunotherapy- versus chemotherapy-based regimens for metastatic esophageal and gastric cancers. (2) Methods: A literature search was conducted, and 18 phase III clinical trials of immune checkpoint inhibitors were selected for analysis. Health care days were calculated based on the number of days associated with receiving therapy and the adverse events reported in the clinical trials. Both the number of health care days and the median overall survival were compared among chemotherapy-only, immunotherapy-only, and chemo-immunotherapy regimens across this cohort of drug registration trials. (3) Results: The estimated median number of health care days was 37 (range of 7–52) days, or 1.2 (range of 0.2–1.7) months, compared to a median survival of 10.2 months across these 18 studies. For the chemotherapy-only regimens, the median number of health care days was 39 (range of 21–51) days, and for chemo-immunotherapy, it was 39 (range of 30–52) days. The immunotherapy-only regimens had fewer days, a median of 28 (range of 24–41), <i>p</i> < 0.05, compared to the other two arms. (4) Conclusions: The chemo-immunotherapy regimens did not add time toxicity compared to chemotherapy alone. The immunotherapy-only regimens had lower time toxicity compared to chemotherapy alone. In the setting of decreased time toxicity and improved overall survival, further development of immunotherapy-based regimens could improve outcomes in advanced esophageal and gastric cancers.https://www.mdpi.com/2072-6694/15/23/5677esophageal cancergastric cancertime toxicitieshospital daysclinical trials |
| spellingShingle | Neha Y. Agrawal Rajat Thawani Corbin P. Edmondson Emerson Y. Chen Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers Cancers esophageal cancer gastric cancer time toxicities hospital days clinical trials |
| title | Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers |
| title_full | Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers |
| title_fullStr | Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers |
| title_full_unstemmed | Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers |
| title_short | Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers |
| title_sort | estimating the time toxicity of contemporary systemic treatment regimens for advanced esophageal and gastric cancers |
| topic | esophageal cancer gastric cancer time toxicities hospital days clinical trials |
| url | https://www.mdpi.com/2072-6694/15/23/5677 |
| work_keys_str_mv | AT nehayagrawal estimatingthetimetoxicityofcontemporarysystemictreatmentregimensforadvancedesophagealandgastriccancers AT rajatthawani estimatingthetimetoxicityofcontemporarysystemictreatmentregimensforadvancedesophagealandgastriccancers AT corbinpedmondson estimatingthetimetoxicityofcontemporarysystemictreatmentregimensforadvancedesophagealandgastriccancers AT emersonychen estimatingthetimetoxicityofcontemporarysystemictreatmentregimensforadvancedesophagealandgastriccancers |